MediciNova CEO Provides Shareholder Update
Key Highlights
- ➤MN-001 Phase 2 missed primary endpoints’ statistical significance in 40-patient trial
- ➤MN-001 significantly improved HDL-C, HDL-P, and early serum triglycerides
- ➤MN-001 reduced triglycerides, liver fat, and body weight versus placebo after 24 weeks
- ➤MN-001 reported no drug-related serious adverse events in the trial
- ➤MN-166 Phase 2b/3 COMBAT-ALS topline results remain on track by year-end
Expert Statements
Yuichi Iwaki, Founder, Chairman, CEO, and President of MediciNova, Inc.
“We believe the observed changes are clinically relevant and that we have met our overarching goal of demonstrating proof of concept of MN-001 in this treatment context.”
Yuichi Iwaki, Founder, Chairman, CEO, and President of MediciNova, Inc.
“We believe MN-001 remains a worthwhile pursuit and are encouraged by signals observed to date.”
LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides shareholders an update on key findings from the recent topline results of its Phase 2 clinical trial evaluating MN-001 for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus in the following letter from CEO Yuichi Iwaki, Ph.D.
We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) (link) in patients with nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia associated with type 2 diabetes mellitus. This randomized, double-blind, placebo-controlled study enrolled 40 patients over a 24-week treatment period and was designed as an exploratory, proof-of-concept trial.
Get started
Create a free account to read the full story.